Unicycive Therapeutics (UNCY) Expected to Announce Quarterly Earnings on Wednesday

Unicycive Therapeutics (NASDAQ:UNCY) is anticipated to announce its results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.4589) per share and revenue of $11.1110 million for the quarter.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.36). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Unicycive Therapeutics Stock Up 0.1%

NASDAQ UNCY opened at $7.95 on Tuesday. The company has a market cap of $212.27 million, a PE ratio of -3.66 and a beta of 1.78. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00. The firm’s 50-day simple moving average is $7.01 and its two-hundred day simple moving average is $6.31.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after purchasing an additional 10,400 shares during the last quarter. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics during the second quarter valued at approximately $55,000. JPMorgan Chase & Co. grew its position in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares during the last quarter. Quadrature Capital Ltd bought a new position in Unicycive Therapeutics during the fourth quarter valued at approximately $226,000. Finally, Citadel Advisors LLC bought a new position in Unicycive Therapeutics during the third quarter valued at approximately $182,000. 40.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on UNCY shares. B. Riley Financial started coverage on shares of Unicycive Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $22.00 price objective on the stock. Guggenheim dropped their price objective on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Benchmark decreased their price target on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a research report on Monday, April 6th. Wall Street Zen cut Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Unicycive Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $24.75.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.